Summit-based Celgene Corporation, a global biopharmaceutical company, announced Thursday that its stockholders approved a two-for-one stock split that will increase the total number of shares of common stock from about 399 million to about 798 million.
Stockholders of record as of June 18 will be entitled to receive one additional share of common stock for each share they hold. The shares are expected to be distributed June 25.
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy